查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083954

癌症診斷市場：2026-2032年全球市場預測（按癌症類型、技術、檢體類型、年齡層、應用和最終用戶分類）

Cancer Diagnostics Market by Cancer Type, Technology, Specimen Type, Age Group, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症診斷市場將成長至 1,126.7 億美元，複合年成長率為 12.26%。

主要市場統計數據
基準年 2025 501.4億美元
預計年份：2026年 561.9億美元
預測年份：2032年 1126.7億美元
複合年成長率 (%) 12.26%

癌症診斷市場執行摘要

癌症診斷正從基於症狀的間歇性檢測轉向基於分子層面資訊的早期發現，涵蓋篩檢、診斷、治療選擇和復發監測。臨床需求龐大。根據世界衛生組織（WHO）下屬國際癌症研究機構（IARC）發布的《2022年全球癌症風險評估報告》（GLOBOCAN 2022），預計全球每年新增癌症病例約2000萬例，癌症死亡病例約970萬例，隨著人口老化和可預防風險因素的持續存在，這一負擔將迅速增加。

癌症診斷領域的變革性變化

分子檢測、數位病理學、先進影像技術和分散式檢體採集的融合正在改變癌症診斷領域。腫瘤譜分析日益融入常規腫瘤診療流程，因為標靶治療和免疫療法通常需要檢驗的生物標記物，例如 EGFR、ALK、HER2、BRCA、MSI、PD-L1 和 NTRK。

人工智慧對癌症診斷的累積影響

人工智慧（AI）正對放射學、病理學、基因組學和工作流程調整等領域產生累積影響。在影像學領域，AI 可輔助進行病灶檢測、分診、分割和時間序列比較；而在病理學領域，AI 則有助於生物標記定量、可疑切片的優先級排序以及提高大量檢體審查的一致性。

癌症診斷的主要區域趨勢

隨著中國、印度、日本、韓國和澳洲加大對腫瘤基礎設施、分子檢查室、數位醫療和大規模篩檢的投資，亞太地區正成為蘊藏重大機會的中心。北美憑藉其在腫瘤領域的高額投入、完善的篩檢項目、伴隨診斷的廣泛應用以及體外診斷醫療設備和檢查室自建檢測（LDT）的成熟監管管道，仍然是癌症診斷領域的領先地區。

針對特定族群的全球癌症診斷應用洞察

東協正致力於提供價格合理的癌症篩檢、提升檢查室能力、培養病理學人才並建立區域通訊網路，以改善其多元化醫療保健系統的可及性。海灣合作理事會（GCC）則大力投資於精準腫瘤學、數位醫療、重症專科護理和國家級舉措，從而推動對先進分子診斷和人工智慧驅動的成像工作流程的需求。

影響癌症診斷需求的關鍵國別洞察

美國在伴隨診斷、腫瘤基因組學、液態生物檢體創新和人工智慧成像等領域主導，這得益於大規模癌症中心和保險公司對臨床效用的嚴格審查。加拿大強調公平篩檢和省級檢查室網路，而墨西哥和巴西則在其公私混合醫療保健系統內擴大病理學、免疫組織化學、HPV檢測、影像學和分子腫瘤學的覆蓋範圍。

癌症診斷領域領導者使用的實用建議

產業領導者應優先考慮經臨床檢驗的診斷方法，這些方法需在檢測、分期、治療選擇、復發監測或診療路徑效率方面展現出可衡量的改善。證據包裝應包括分析表現、真實世界臨床效用、衛生經濟影響以及適用於腫瘤科醫生、病理學家、放射科醫生、實驗室管理人員和公共篩檢計畫的工作流程。

癌症診斷智慧的調查方法

本執行摘要是基於權威公共資訊來源的二手研究，包括世界衛生組織 (WHO)、國際癌症研究機構全球癌症聯盟 (IARC GLOBOCAN)、國家癌症實驗室、監管機構、同行評審的腫瘤學文獻、臨床指南制定機構和公共衛生計畫的相關文件。市場分析考慮了流行病學、診斷指南、技術應用現狀、報銷機制、監管要求和區域醫療服務能力。

結論：癌症診斷是精準腫瘤學的驅動力

癌症診斷正成為精準腫瘤學、公共衛生篩檢和以價值為導向的癌症治療的核心支柱。這一趨勢的促進因素包括癌症發病率的上升、生物標記相關療法的普及、人工智慧輔助的診斷結果解讀，以及分子診斷、病理診斷、細胞學和影像學檢查等技術的日益普及。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癌症診斷市場：依癌症類型分類

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 攝護腺癌

第8章：癌症診斷市場：依技術分類

  • 流式細胞技術
    • 細胞分選
    • 多參數流式細胞技術
  • 影像
    • 電腦斷層掃描
    • 磁振造影
    • 正子斷層掃描
    • 超音波
  • 免疫組織化學
    • 顯色方法
    • 螢光法
  • 原位雜合反應
  • 分子診斷
    • 微陣列
    • PCR
    • 順序

第9章：癌症診斷市場：依檢體類型分類

  • 組織
  • 血
  • 骨髓
  • 尿
  • 唾液

第10章 癌症診斷市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第11章 癌症診斷市場：依應用領域分類

  • 篩檢和早期檢測
  • 初步診斷
  • 預後和風險分層
  • 治療方案
  • 治療監測
  • 復發監測

第12章 癌症診斷市場：依最終用戶分類

  • 門診治療
  • 診斷實驗室
  • 醫院
  • 研究機構

第13章 癌症診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 癌症診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Corporation
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436145BF8B0C

The Cancer Diagnostics Market is projected to grow by USD 112.67 billion at a CAGR of 12.26% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 50.14 billion
Estimated Year [2026] USD 56.19 billion
Forecast Year [2032] USD 112.67 billion
CAGR (%) 12.26%

Cancer Diagnostics Executive Summary

Cancer diagnostics is moving from episodic, symptom-led testing toward earlier, molecularly informed detection across screening, diagnosis, treatment selection, and recurrence monitoring. The clinical need is substantial: the World Health Organization's IARC GLOBOCAN 2022 estimates about 20 million new cancer cases and 9.7 million cancer deaths worldwide, with the burden expected to rise sharply as populations age and exposure to preventable risk factors persists.

Demand is being shaped by high-volume pathology, imaging, companion diagnostics, next-generation sequencing, liquid biopsy, immunohistochemistry, cytology, HPV testing, and point-of-care testing. Health systems are prioritizing diagnostics that shorten time to diagnosis, improve tumor characterization, support precision oncology, and expand access to guideline-recommended screening for breast, cervical, colorectal, lung, and prostate cancers.

Transformative Shifts in the Cancer Diagnostics Landscape

The cancer diagnostics landscape is being transformed by the convergence of molecular testing, digital pathology, advanced imaging, and decentralized sample collection. Tumor profiling is increasingly embedded in routine oncology workflows because targeted therapies and immunotherapies often require validated biomarkers such as EGFR, ALK, HER2, BRCA, MSI, PD-L1, and NTRK.

At the same time, laboratories face pressure to improve turnaround time, reimbursement evidence, sample traceability, and interoperability with electronic health records. The shift from single-gene assays to multi-gene panels and comprehensive genomic profiling is raising expectations for analytical validity, clinical utility, external quality assessment, and standardized reporting across hospital laboratories, reference laboratories, and oncology networks.

Cumulative Impact of Artificial Intelligence on Cancer Diagnostics

Artificial intelligence is having a cumulative impact across radiology, pathology, genomics, and workflow orchestration. In imaging, AI supports lesion detection, triage, segmentation, and longitudinal comparison, while in pathology it helps quantify biomarkers, prioritize suspicious slides, and improve consistency in high-volume review.

Regulators are increasingly evaluating AI-enabled medical devices, and the U.S. FDA has listed hundreds of authorized AI and machine-learning-enabled devices, with radiology representing the largest category. For cancer diagnostics, the practical value of AI depends on prospective validation, bias monitoring, cybersecurity, explainability, human oversight, and integration into clinician-supervised decision pathways rather than standalone automation.

Key Regional Insights Across Cancer Diagnostics

Asia-Pacific is becoming a major opportunity base as China, India, Japan, South Korea, and Australia invest in oncology infrastructure, molecular laboratories, digital health, and population screening. North America remains a leading region for cancer diagnostics due to high oncology spending, established screening programs, broad adoption of companion diagnostics, and mature regulatory pathways for in vitro diagnostics and laboratory-developed tests.

Latin America is improving access through public-private diagnostic networks, with Brazil and Mexico acting as important demand centers for pathology, imaging, HPV testing, and molecular oncology. Europe is shaped by national cancer plans, organized screening, IVDR implementation, and cross-border research networks, while the European Health Data Space is designed to strengthen data-driven oncology innovation. The Middle East is expanding precision medicine through tertiary cancer centers, digital health programs, and national genomics initiatives, while Africa's priority is scalable access to pathology, HPV testing, imaging, and basic oncology diagnostics in line with WHO cancer control goals.

Key Group Insights for Global Cancer Diagnostics Adoption

ASEAN is focused on affordable cancer screening, laboratory capacity, pathology workforce development, and regional referral networks to improve access across diverse health systems. The GCC is investing heavily in precision oncology, digital health, centralized specialty care, and national genomics initiatives, strengthening demand for advanced molecular diagnostics and AI-enabled imaging workflows.

The European Union is pivotal because IVDR, cancer screening recommendations, and Europe's Beating Cancer Plan influence diagnostic quality, evidence generation, and market access. BRICS countries represent large-volume growth driven by cancer burden, expanding middle-class access, public oncology investment, and domestic diagnostic manufacturing. The G7 anchors high-value adoption through advanced oncology reimbursement, clinical trial density, biomarker-driven therapy use, and regulatory science, while NATO countries overlap significantly with major diagnostic innovation hubs in North America and Europe, supporting resilient supply chains for reagents, imaging equipment, semiconductors, cloud infrastructure, and cybersecurity-enabled health data systems.

Key Country Insights Shaping Cancer Diagnostics Demand

The United States leads in companion diagnostics, oncology genomics, liquid biopsy innovation, and AI-enabled imaging, supported by large cancer centers and payer scrutiny around clinical utility. Canada emphasizes equitable screening and provincial laboratory networks, while Mexico and Brazil are expanding access to pathology, immunohistochemistry, HPV testing, imaging, and molecular oncology within mixed public-private systems.

The United Kingdom, Germany, France, Italy, and Spain are advancing national cancer strategies, genomics programs, organized screening, and digital pathology adoption, while Russia maintains demand for imaging and pathology modernization. China is scaling domestic IVD innovation and oncology testing capacity; India is prioritizing affordable diagnostics, HPV testing, and tertiary cancer care expansion; Japan and South Korea remain leaders in precision oncology, companion diagnostics, and high-quality imaging; and Australia combines strong screening participation, research infrastructure, and digital health adoption.

Actionable Recommendations for Cancer Diagnostics Leaders

Industry leaders should prioritize clinically validated diagnostics that demonstrate measurable improvements in detection, staging, therapy selection, recurrence monitoring, or care pathway efficiency. Evidence packages should include analytical performance, real-world clinical utility, health-economic impact, and workflow fit for oncologists, pathologists, radiologists, laboratory directors, and public screening programs.

Organizations should also invest in interoperable platforms, AI governance, decentralized sample logistics, cybersecurity, and regulatory-ready quality systems. Strategic partnerships with cancer centers, payers, biobanks, public health agencies, and screening programs can accelerate adoption, while tiered pricing, local training, and regional manufacturing can improve access in emerging markets.

Research Methodology for Cancer Diagnostics Intelligence

This executive summary is based on secondary research from authoritative public sources, including WHO, IARC GLOBOCAN, national cancer institutes, regulatory agencies, peer-reviewed oncology literature, clinical guideline bodies, and public health program documentation. Market interpretation considers epidemiology, diagnostic guidelines, technology adoption, reimbursement structures, regulatory requirements, and regional healthcare capacity.

The analysis triangulates data across disease burden, screening participation, installed diagnostic infrastructure, regulatory developments, precision medicine adoption, and evidence standards for oncology testing. Insights are validated through consistency checks across clinical evidence, policy direction, and technology deployment patterns to support decision-making for manufacturers, laboratories, investors, and healthcare providers.

Conclusion: Cancer Diagnostics as a Precision Oncology Engine

Cancer diagnostics is becoming a central pillar of precision oncology, public health screening, and value-based cancer care. Momentum is being driven by rising cancer incidence, biomarker-linked therapies, AI-enabled interpretation, and expanding access to molecular, pathology, cytology, and imaging-based diagnostics.

The most competitive organizations will combine scientific validity, operational scalability, regulatory discipline, data security, and equitable access strategies. As health systems seek earlier detection and more personalized treatment, cancer diagnostics will remain one of the most strategically important segments of global healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Diagnostics Market, by Cancer Type

  • 7.1. Hematological Cancers
    • 7.1.1. Leukemia
    • 7.1.2. Lymphoma
    • 7.1.3. Multiple Myeloma
  • 7.2. Solid Tumors
    • 7.2.1. Breast Cancer
    • 7.2.2. Colorectal Cancer
    • 7.2.3. Lung Cancer
    • 7.2.4. Prostate Cancer

8. Cancer Diagnostics Market, by Technology

  • 8.1. Flow Cytometry
    • 8.1.1. Cell Sorting
    • 8.1.2. Multiparameter Flow Cytometry
  • 8.2. Imaging
    • 8.2.1. Computed Tomography
    • 8.2.2. Magnetic Resonance Imaging
    • 8.2.3. Positron Emission Tomography
    • 8.2.4. Ultrasound
  • 8.3. Immunohistochemistry
    • 8.3.1. Chromogenic
    • 8.3.2. Fluorescent
  • 8.4. In Situ Hybridization
  • 8.5. Molecular Diagnostics
    • 8.5.1. Microarray
    • 8.5.2. PCR
    • 8.5.3. Sequencing

9. Cancer Diagnostics Market, by Specimen Type

  • 9.1. Tissue
  • 9.2. Blood
  • 9.3. Bone Marrow
  • 9.4. Urine
  • 9.5. Saliva

10. Cancer Diagnostics Market, by Age Group

  • 10.1. Pediatric
  • 10.2. Adult
  • 10.3. Geriatric

11. Cancer Diagnostics Market, by Application

  • 11.1. Screening & Early Detection
  • 11.2. Initial Diagnosis
  • 11.3. Prognosis & Risk Stratification
  • 11.4. Therapy Selection
  • 11.5. Treatment Monitoring
  • 11.6. Recurrence Monitoring

12. Cancer Diagnostics Market, by End User

  • 12.1. Ambulatory Care
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Cancer Diagnostics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Agilent Technologies, Inc.
  • 17.3. Becton, Dickinson and Company
  • 17.4. Bio-Rad Laboratories, Inc.
  • 17.5. bioMerieux SA
  • 17.6. Canon Medical Systems Corporation
  • 17.7. Danaher Corporation
  • 17.8. DiaSorin S.p.A.
  • 17.9. F. Hoffmann-La Roche Ltd
  • 17.10. Fujifilm Corporation
  • 17.11. GE HealthCare Technologies Inc.
  • 17.12. Hologic, Inc.
  • 17.13. Illumina, Inc.
  • 17.14. Myriad Genetics, Inc.
  • 17.15. NeoGenomics Laboratories, Inc.
  • 17.16. PerkinElmer, Inc.
  • 17.17. QIAGEN N.V.
  • 17.18. Quest Diagnostics Incorporated
  • 17.19. Siemens Healthineers AG
  • 17.20. Sysmex Corporation
  • 17.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL SORTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL SORTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL SORTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPARAMETER FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPARAMETER FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPARAMETER FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHROMOGENIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHROMOGENIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHROMOGENIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FLUORESCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FLUORESCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FLUORESCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SCREENING & EARLY DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SCREENING & EARLY DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SCREENING & EARLY DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PROGNOSIS & RISK STRATIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROGNOSIS & RISK STRATIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PROGNOSIS & RISK STRATIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL THERAPY SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL THERAPY SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AMBULATORY CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AMBULATORY CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL AMBULATORY CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. GCC CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. G7 CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 276. G7 CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. G7 CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. NATO CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 285. NATO CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 288. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 289. NATO CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. NATO CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 339. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 346. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 361. GERMANY CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 362. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 363. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 364. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 365. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 366. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 367. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 368. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 369. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 370. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 371. GERMANY CANCER DIAGNOS